Clinical Trials Logo

Hemophilia A clinical trials

View clinical trials related to Hemophilia A.

Filter by:

NCT ID: NCT00281333 Terminated - Hemophilia A Clinical Trials

The Influence of "Karate" on Bleeding in Hemophilic Patients.

Start date: n/a
Phase: N/A
Study type: Interventional

Hemophilia patients tend to lower their physical activity level due to the fear of increasing bleeding episodes. Although recent literature has shown that with routine muscle strengthening and physical activity, the frequency and duration of bleeds was reduced. Our study has built a routine of strength training exercises and karate training. The study is built in two stages, each stage being three months. The participants fill out a bleeding diary that includes information from the previous six months. It includes place of bleed, duration, pain level, spontaneous or traumatic bleed, factor replacement and joint limitation. Before the exercise, the participants are tested for muscle strength and endurance. The bleeding diary will be filled out following the first three months and the second phase as will the muscle strength and endurance. We are hoping to see a drastic reduction of bleeding episodes occurring especially from spontaneous bleeds.

NCT ID: NCT00212472 Terminated - Clinical trials for Hemophilia A With Inhibitors

International Immune Tolerance Study

Start date: July 2002
Phase: N/A
Study type: Interventional

The purpose of this study is to see if a low-dose arm or a high dose-arm of immune tolerance is more effective in eliminating inhibitors in patients with hemophilia A.

NCT ID: NCT00076557 Terminated - Hemophilia B Clinical Trials

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

Start date: January 2004
Phase: Phase 1/Phase 2
Study type: Interventional

In this study a modified virus called adeno-associated virus (AAV) will be used to transfer a normal gene for human clotting factor IX into patients with severe hemophilia B (AAV human Factor IX vector). Gene therapy is a very new medical technique being used in a number of clinical studies for diseases such as cancer and cystic fibrosis. At this time, the U.S. Food and Drug Administration has approved no gene transfer products for commercial use. To date, 8 subjects have received AAV vector in the muscle for a hemophilia B trial by intramuscular injection, and, to date, 6 subjects have been treated with AAV vector in the current hemophilia B liver trial. Eleven cystic fibrosis subjects have received AAV vector into their nasal sinuses or lungs to date. In this study, AAV human Factor IX vector will be injected into the liver using a catheter inserted into a large blood vessel (called the proper hepatic artery or the right hepatic artery).